^
Association details:
| Biomarker: | EGFR mutation + TP53 mutation + ARID1A mutation |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Tagrisso (osimertinib) (EGFR inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Co-occurring Alterations in Multiple Tumor Suppressor Genes are Associated with Worse Outcomes in Patients with EGFR-mutant Lung Cancer
Published date:
10/05/2023
Excerpt:
Patients with EGFR-mutant NSCLC treated with EGFR-TKIs who had tumor genomic profiling were included. Alterations in TP53 and five additional TSGs (RB1, NF1, ARID1A, BRCA1 and PTEN) were used to stratify the cohort into three subgroups: patients with tumors harboring a TP53 mutation plus a mutation in ≥1 additional TSG (TP53mut/TSGmut), a TP53 mutation without additional TSG mutations (TP53mut/TSGwt), and TP53wt....Inferior outcomes in TP53mut/TSGmut tumors were also seen in patients receiving osimertinib as second-line therapy.
DOI:
https://doi.org/10.1016/j.jtho.2023.10.001
